Adverum Biotechnologies to Present at 39th Annual J.P. Morgan Healthcare Conference
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage gene therapy company focusing on ocular and rare diseases, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:50 a.m. ET. The presentation will highlight the company’s innovative gene therapy candidate, ADVM-022, aimed at treating wet age-related macular degeneration and diabetic macular edema. A live webcast of the event will be available on Adverum's website, and an archived version will be accessible for 30 days following the presentation.
- None.
- None.
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 10:50 a.m. ET.
The live webcast will be accessible under Events and Presentations in the Investors section of the company's website. This archived webcast will be available on the Adverum website following the presentation for 30 days.
About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.
FAQ
When is Adverum Biotechnologies presenting at the J.P. Morgan Healthcare Conference?
What is the focus of Adverum Biotechnologies?
What is the gene therapy candidate ADVM-022 used for?
Where can I watch the Adverum Biotechnologies presentation?
What platform is Adverum Biotechnologies listed on?
